Article and Video CATEGORIES
The ASCO meeting I'm at right now is so busy that there really isn't time to write a new post (though I'm still "tweeting from the meeting"). Though the talk show hows just air re-runs of old shows when they're on vacation, I'm trying to continue to add new content to the website during this time (and it's about as far from a vacation as anyone has in Orlando).
Here's an interview I did with Dr. Suresh Ramalingam, medical oncologist and Director of the Thoracic Oncology Program at Winship Cancer Institute at Emory University. It covers the current status of initial treatment for advanced NSCLC, including controversies and shifting standards for first line and then the transition into maintenance therapy. There's also an associated slide set (as a pdf file), a transcript, and a link to the audio (mp3) version.
[powerpress]
ramalingam-podcast-figures-on-first-line-rx-and-maint2
ramalingam-first-line-and-maintenance-rx-transcript
Ramalingam First Line and Maintenance Rx for Adv NSCLC Audio Podcast
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…